Vaccinex Inc Stock Price, News & Analysis

Vaccinex, a biotechnology company focusing on neurodegenerative diseases, has successfully completed enrollment for its SIGNAL-AD clinical trial, aimed at evaluating pepinemab in patients with mild Alzheimer's Disease. The trial, which included 40 patients, is designed to assess safety and cognitive effects over a 52-week period. Results are expected in mid-2024. The company builds on previous positive data from its Huntington’s Disease study, reinforcing the potential of pepinemab to address neuroinflammation. Moreover, FDA feedback on a planned Phase 3 study for Huntington’s Disease is anticipated by May 16, 2023. The ongoing SIGNAL-AD trial has been supported financially by key organizations in Alzheimer’s research.

Vaccinex, Inc. (Nasdaq: VCNX), a biotechnology firm focusing on innovative treatments for neurodegenerative diseases and cancer, announced the publication of a significant research paper in Nature Communications on April 12, 2023. The study highlights their novel ActivMAb^® platform, which presents a new way to study G protein-coupled receptors (GPCRs) and ion channels, deemed challenging to drug.

By utilizing a Vaccinia-based system, the research demonstrates the creation of diverse libraries of GPCR variants, enhancing expression and stability while preserving their functional characteristics. This innovation is expected to aid in drug discovery and improve the study of GPCRs, critical drug targets involved in many physiological processes. Vaccinex's lead drug candidate, pepinemab, continues clinical trials for Alzheimer's and various cancers.

Vaccinex, Inc. (Nasdaq: VCNX) announced the closing of a private placement on March 30, 2023, raising $2.04 million by selling 4,975,608 shares at $0.41 per share. Major participants included Dr. Maurice Zauderer, CEO, and Albert D. Friedberg, Chairman, who invested a combined $2.0 million. A commitment for an additional $2.96 million was made by Friedberg's entity, totaling $5.0 million in new financing. Funds will be used for the development of pepinemab, targeted at Alzheimer’s disease and cancer. Detailed terms will be outlined in a future SEC filing.

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biopharmaceutical firm, revealed financial results for Q4 2022 and an update on its key clinical programs. The company is set to complete enrollment for the SIGNAL-AD Alzheimer's study by April 2023, with topline data expected in mid-2024. It also achieved enrollment of 36 patients in the KEYNOTE B84 study for head and neck cancer, anticipating interim analysis results by May 2023. Financially, cash and equivalents totaled $6.4 million as of December 31, 2022, down from $8.6 million in 2021. Research and development expenses decreased from $17.2 million in 2021 to $14.0 million in 2022, while the net loss per share improved from $(0.78) to $(0.47).

Vaccinex Inc. (Nasdaq: VCNX) is showcasing insights on pepinemab's action mechanism against neurodegenerative diseases at the AAIC Advancements: Immunity conference on March 24, 2023. COO Elizabeth Evans will discuss findings on semaphorin 4D's (SEMA4D) role in Huntington’s Disease and Alzheimer’s Disease.

The ongoing clinical trial, SIGNAL AD, is pivotal, with topline data expected in mid-2024. The presentation emphasizes targeting neuroinflammation as a novel treatment approach. Vaccinex's innovative strategy aims to inhibit SEMA4D to combat chronic neurodegenerative conditions.

Vaccinex, Inc. (Nasdaq: VCNX) announced a Phase Ib/2 study evaluating pepinemab in combination with avelumab for patients with metastatic pancreatic adenocarcinoma (PDAC). The trial, conducted at the University of Rochester, aims to assess safety and efficacy in overcoming the immunosuppressive tumor microenvironment. Sponsored by Vaccinex and supported by the Gateway Discovery Award, the study is critical given PDAC's low 5-year survival rate of 5-10%. It focuses on enhancing immune response by reversing immunosuppression within the tumor microenvironment. Pepinemab's favorable safety profile in earlier studies could offer new treatment hope for PDAC patients.

Vaccinex, Inc. (Nasdaq: VCNX) has enrolled 36 subjects in the Phase 1b/2 KEYNOTE-B84 study to evaluate pepinemab combined with Merck's KEYTRUDA for treating recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). An interim analysis is planned upon completion of tumor assessments, with results expected in mid-2023. The study aims to determine the safety and efficacy of this combination therapy, particularly in patients with low PD-L1 expression. Pepinemab is noted for its potential to enhance immune responses while maintaining safety profiles associated with KEYTRUDA.

Vaccinex, Inc. announced that its licensee, Surface Oncology, has initiated a Phase 1/2 clinical trial for SRF114, an antibody discovered using Vaccinex’s ActivMAb® platform. This is a significant milestone as it validates the ActivMAb® technology. SRF114 targets CCR8 to selectively deplete immuno-suppressive tumor T regulatory cells, potentially positioning it as a best-in-class therapy for advanced solid tumors. Under the licensing agreement, Vaccinex stands to benefit from milestone payments and royalties on sales.